Payment overview · 2025
General Payments
$418.83
6 reported records · 3 companies
Healthcare provider profile · identity verified
William J Sullivan, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · FRONTENAC, KS · NPI 1093805897
Verified facts
What the public records show
CMS Open Payments records show William J Sullivan, D.O. received $418.83 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $170.90 | 40.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 29.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.93 | 29.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $418.83 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $122.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 63 |
| Losartan Potassium | Losartan Potassium | 249 | 57 |
| Alprazolam | Alprazolam | 225 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 56 |
| Gabapentin | Gabapentin | 215 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 38 |
| Lisinopril | Lisinopril | 184 | 49 |
| Metformin Hcl | Metformin Hcl | 183 | 43 |
| Furosemide | Furosemide | 179 | 33 |
| Omeprazole | Omeprazole | 168 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 39 |
| Potassium Chloride | Potassium Chloride | 161 | 36 |
| Meloxicam | Meloxicam | 154 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 26 |
| Eliquis | Apixaban | 118 | 22 |
| Sertraline Hcl | Sertraline Hcl | 117 | 21 |
| Finasteride | Finasteride | 112 | 22 |
| Allopurinol | Allopurinol | 109 | 27 |
| Tramadol Hcl | Tramadol Hcl | 109 | 32 |
| Lorazepam | Lorazepam | 100 | 11 |
| Famotidine | Famotidine | 98 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 11 |
| Montelukast Sodium | Montelukast Sodium | 88 | 24 |
| Trazodone Hcl | Trazodone Hcl | 88 | 17 |
| Prednisone | Prednisone | 84 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 19 |
| Lovastatin | Lovastatin | 75 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 72 | 13 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 13 |
| Atenolol | Atenolol | 66 | 11 |
| Buspirone Hcl | Buspirone Hcl | 65 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Pregabalin | Pregabalin | 65 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 13 |
| Carvedilol | Carvedilol | 57 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 33 |
| Estradiol | Estradiol | 55 | 15 |
| Simvastatin | Simvastatin | 55 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 12 |
| Sucralfate | Sucralfate | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 21 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 27 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Naproxen | Naproxen | 38 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 30 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 16 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Cefprozil | Cefprozil | 23 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Climara Pro | Estradiol/Levonorgestrel | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $418.83 · 6 records | PFIZER INC. | BREZTRI, MOUNJARO, NURTEC ODT | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error